Drug Trial News

RSS

Most depressed patients must make multiple attempts before finding an effective antidepressant

UT Southwestern Medical Center psychiatrists are leading a national clinical trial to find biomarkers that can better predict how people suffering from depression will respond to medications so physicians eventually can personalize treatments.

16 May 2012

First patient included in the phase II study of Amphinex® in head and neck cancer patients

PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the first patient has been included in the phase II study of Amphinex in combination with the cytotoxic agent bleomycin in head and neck cancer patients, called the ENHANCE study. The first patient was included at the National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Germany. NCT is a joint project of the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Thoraxklinik Heidelberg and Deutsche Krebshilfe (German Cancer Aid).

16 May 2012

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults.

16 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced metastatic melanoma.

16 May 2012

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.

16 May 2012

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia.

16 May 2012

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that it has successfully completed the first cohort in a U.S. multi-center Phase 1b dose-escalation trial of its cancer-targeted molecular radiotherapeutic compound I-131-CLR1404 (HOT) in cancer patients with advanced solid tumors.

16 May 2012

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand.

15 May 2012

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Cubist Pharmaceuticals, Inc. today announced that the results from the Phase 2 studies of CB-5945 (formerly ADL5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC) will be presented at the 31st Annual Scientific Meeting of the American Pain Society taking place May 16 to 19, 2012, in Honolulu and during Digestive Disease Week 2012 taking place May 19 to 22, 2012, in San Diego.

15 May 2012

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.

15 May 2012

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

BioAlliance Pharma commences Livatag phase III trial in hepatocellular carcinoma

BioAlliance Pharma SA, a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag(doxorubicin Transdrug), as scheduled in the advancement calendar of the project.

15 May 2012

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Eli Lilly and Company will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 – 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.

15 May 2012

Fibrocell submits azficel-T Phase II study protocol with FDA to treat restrictive burn scars

Fibrocell Science, Inc. announced today that is has submitted to the U.S. Food & Drug Administration (FDA) the company's Phase II clinical study protocol to evaluate the safety and efficacy of Fibrocell's lead therapy, azficel-T, in improving the range of motion, function and flexibility, in patients with existing restrictive burn scars.

15 May 2012

Phase II trial to examine effects of resveratrol on individuals with mild to moderate dementia

A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders Program, is the lead investigator for the national study.

14 May 2012

Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

S.L.A. Pharma AG has announced clinically and statistically significant top-line data from their Phase 2 double blind randomised placebo controlled study. The study was designed to evaluate the safety and efficacy of 4 doses of Nalcol, a novel oral formulation of naloxone, in treating opioid induced constipation (OIC) in patients with persistent non-cancer pain.

14 May 2012

Lenalidomide delays progression of multiple myeloma after stem cell transplant

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.

14 May 2012

Chronic asthma sufferers may have new hope for relief due to two BWH research studies

Chronic asthma sufferers may have new hope for relief due to two new research studies that are getting underway at Brigham and Women's Hospital (BWH). Researchers from BWH's Asthma Research Center are exploring whether two new therapies will relieve asthma symptoms.

14 May 2012

Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD

Cytochroma today announced positive clinical trial results for its lead product, CTAP101 Capsules. In a recently completed Phase 2b trial, CTAP101 Capsules effectively and safely lowered elevated plasma intact parathyroid hormone (iPTH) in patients with Stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

11 May 2012

Drug Trial News

Most depressed patients must make multiple attempts before finding an effective antidepressant

First patient included in the phase II study of Amphinex® in head and neck cancer patients

Achaogen’s plazomicin and levofloxacin safe and effective in treating cUTI, acute pyelonephritis

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Galectin Therapeutics commences Phase 1/2 trial of new treatment combination for advanced MM

Positive data from Theraclone Sciences’ TCN-032 Phase 1 trial on influenza A infection

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI

Novelos completes I-131-CLR1404 Phase 1b trial on advanced solid tumors

Svelte completes enrollment in DIRECT drug-eluting stent study

Cubist announces results from CB-5945 Phase 2 studies on chronic non-cancer pain, OIC

Pearl Therapeutics to present PT003 Phase 2b study on COPD at ATS meeting

Smoked cannabis may be an effective treatment for spasticity

BioAlliance Pharma commences Livatag phase III trial in hepatocellular carcinoma

Lilly to present oncology data from more than 25 studies at ASCO annual meeting

Fibrocell submits azficel-T Phase II study protocol with FDA to treat restrictive burn scars

Phase II trial to examine effects of resveratrol on individuals with mild to moderate dementia

Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

Lenalidomide delays progression of multiple myeloma after stem cell transplant

Chronic asthma sufferers may have new hope for relief due to two BWH research studies

Positive results from Cytochroma CTAP101 Phase 2b clinical trial for CKD

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News